ID   NCOA2_RAT               Reviewed;        1465 AA.
AC   Q9WUI9;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   24-JAN-2024, entry version 164.
DE   RecName: Full=Nuclear receptor coactivator 2;
DE            Short=NCoA-2;
DE   AltName: Full=Transcriptional intermediary factor 2;
GN   Name=Ncoa2; Synonyms=Tif2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=9742117; DOI=10.1128/mcb.18.10.6001;
RA   Leers J., Treuter E., Gustafsson J.-A.;
RT   "Mechanistic principles in NR box-dependent interaction between nuclear
RT   hormone receptors and the coactivator TIF2.";
RL   Mol. Cell. Biol. 18:6001-6013(1998).
RN   [2]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-396; SER-493; SER-499 AND
RP   SER-699, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Transcriptional coactivator for steroid receptors and nuclear
CC       receptors. Coactivator of the steroid binding domain (AF-2) but not of
CC       the modulating N-terminal domain (AF-1). Required with NCOA1 to control
CC       energy balance between white and brown adipose tissues. Critical
CC       regulator of glucose metabolism regulation, acts as a RORA coactivator
CC       to specifically modulate G6PC1 expression. Involved in the positive
CC       regulation of the transcriptional activity of the glucocorticoid
CC       receptor NR3C1 by sumoylation enhancer RWDD3. Positively regulates the
CC       circadian clock by acting as a transcriptional coactivator for the
CC       CLOCK-BMAL1 heterodimer. {ECO:0000250|UniProtKB:Q15596,
CC       ECO:0000250|UniProtKB:Q61026}.
CC   -!- SUBUNIT: Present in a complex containing NCOA3, IKKA, IKKB, IKBKG and
CC       CREBBP (By similarity). Present in a complex containing CARM1 and
CC       EP300/P300 (By similarity). Interacts (via C-terminus) with CREBBP (By
CC       similarity). Interacts (via LXXLL 1, 2 and 3 motifs) with RORA (via AF-
CC       2 motif) (By similarity). Interacts (via LXXLL 1, 2 and 3 motifs) with
CC       RORC (via AF-2 motif) (By similarity). Interacts with APEX1 (By
CC       similarity). Interacts with BMAL1 (By similarity). Interacts with CARM1
CC       (By similarity). Interacts with CASP8AP2 (By similarity). Interacts
CC       with CLOCK (By similarity). Interacts with DDX5 (By similarity).
CC       Interacts with ESR1 (By similarity). Interacts with HIF1A (By
CC       similarity). Interacts with NCOA1 (By similarity). Interacts with
CC       NR4A1/Nur77 (By similarity). Interacts with NR4A3; potentiates the
CC       activity of the NR4A3 (By similarity). Interacts with NR1H3 (By
CC       similarity). Interacts with NR3C1 (By similarity). Interacts with NR3C2
CC       (By similarity). Interacts with PSMB9 (By similarity). Interacts with
CC       RARA (By similarity). Interacts with RXRA (By similarity). Interacts
CC       with RWDD3 (By similarity). Interacts with TTLL5/STAMP (By similarity).
CC       {ECO:0000250|UniProtKB:Q15596, ECO:0000250|UniProtKB:Q61026}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:Q15596}.
CC   -!- DOMAIN: Contains four Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs. The LXXLL
CC       motifs are essential for the association with nuclear receptors and
CC       are, at least in part, functionally redundant.
CC       {ECO:0000250|UniProtKB:Q15596}.
CC   -!- DOMAIN: The LLXXLXXXL motif is involved in transcriptional coactivation
CC       and CREBBP/CBP binding. {ECO:0000250|UniProtKB:Q15596}.
CC   -!- DOMAIN: Contains 2 C-terminal transcription activation domains (AD1 and
CC       AD2) that can function independently. {ECO:0000250|UniProtKB:Q15596}.
CC   -!- PTM: Acetylated. Deacetylation at Lys-780 by SIRT6 stimulates its
CC       ability to coactivate PPARA. {ECO:0000250|UniProtKB:Q61026}.
CC   -!- SIMILARITY: Belongs to the SRC/p160 nuclear receptor coactivator
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF136943; AAD24587.1; -; mRNA.
DR   RefSeq; NP_114010.1; NM_031822.1.
DR   PDB; 1XLS; X-ray; 2.96 A; I/J/K/L/M/N/O/P=740-756.
DR   PDB; 3HLV; X-ray; 3.00 A; C/D=686-698.
DR   PDB; 3HM1; X-ray; 2.33 A; C/D=686-698.
DR   PDB; 3L03; X-ray; 1.90 A; C/D=686-698.
DR   PDBsum; 1XLS; -.
DR   PDBsum; 3HLV; -.
DR   PDBsum; 3HM1; -.
DR   PDBsum; 3L03; -.
DR   AlphaFoldDB; Q9WUI9; -.
DR   SMR; Q9WUI9; -.
DR   STRING; 10116.ENSRNOP00000011026; -.
DR   iPTMnet; Q9WUI9; -.
DR   PhosphoSitePlus; Q9WUI9; -.
DR   PaxDb; 10116-ENSRNOP00000011026; -.
DR   GeneID; 83724; -.
DR   KEGG; rno:83724; -.
DR   UCSC; RGD:620108; rat.
DR   AGR; RGD:620108; -.
DR   CTD; 10499; -.
DR   RGD; 620108; Ncoa2.
DR   eggNOG; KOG3561; Eukaryota.
DR   InParanoid; Q9WUI9; -.
DR   PhylomeDB; Q9WUI9; -.
DR   Reactome; R-RNO-159418; Recycling of bile acids and salts.
DR   Reactome; R-RNO-192105; Synthesis of bile acids and bile salts.
DR   Reactome; R-RNO-193368; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol.
DR   Reactome; R-RNO-193807; Synthesis of bile acids and bile salts via 27-hydroxycholesterol.
DR   Reactome; R-RNO-211976; Endogenous sterols.
DR   Reactome; R-RNO-3214847; HATs acetylate histones.
DR   Reactome; R-RNO-400206; Regulation of lipid metabolism by PPARalpha.
DR   Reactome; R-RNO-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3.
DR   Reactome; R-RNO-9707564; Cytoprotection by HMOX1.
DR   EvolutionaryTrace; Q9WUI9; -.
DR   PRO; PR:Q9WUI9; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0043197; C:dendritic spine; IDA:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISO:RGD.
DR   GO; GO:0005667; C:transcription regulator complex; ISO:RGD.
DR   GO; GO:0017162; F:aryl hydrocarbon receptor binding; ISO:RGD.
DR   GO; GO:0003682; F:chromatin binding; ISO:RGD.
DR   GO; GO:0070182; F:DNA polymerase binding; IPI:RGD.
DR   GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:RGD.
DR   GO; GO:0035259; F:nuclear glucocorticoid receptor binding; IPI:RGD.
DR   GO; GO:0016922; F:nuclear receptor binding; IPI:RGD.
DR   GO; GO:0030374; F:nuclear receptor coactivator activity; ISS:UniProtKB.
DR   GO; GO:0042974; F:nuclear retinoic acid receptor binding; IPI:RGD.
DR   GO; GO:0046965; F:nuclear retinoid X receptor binding; IPI:RGD.
DR   GO; GO:0046966; F:nuclear thyroid hormone receptor binding; IPI:RGD.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0019904; F:protein domain specific binding; ISO:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0001162; F:RNA polymerase II intronic transcription regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; ISO:RGD.
DR   GO; GO:0003713; F:transcription coactivator activity; ISS:UniProtKB.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IBA:GO_Central.
DR   GO; GO:1904017; P:cellular response to Thyroglobulin triiodothyronine; ISO:RGD.
DR   GO; GO:0021549; P:cerebellum development; IEP:RGD.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; ISO:RGD.
DR   GO; GO:0045475; P:locomotor rhythm; ISO:RGD.
DR   GO; GO:0008584; P:male gonad development; IEP:RGD.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0045925; P:positive regulation of female receptivity; IMP:RGD.
DR   GO; GO:2000324; P:positive regulation of glucocorticoid receptor signaling pathway; IMP:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:RGD.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:RGD.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; ISO:RGD.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; ISS:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0032570; P:response to progesterone; ISO:RGD.
DR   CDD; cd18950; bHLH-PAS_NCoA2_SRC2; 1.
DR   CDD; cd00130; PAS; 1.
DR   Gene3D; 4.10.280.10; Helix-loop-helix DNA-binding domain; 1.
DR   Gene3D; 6.10.140.20; Nuclear receptor coactivator, Ncoa-type, interlocking domain; 1.
DR   Gene3D; 3.30.450.20; PAS domain; 2.
DR   IDEAL; IID50249; -.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR010011; NCO_DUF1518.
DR   InterPro; IPR032565; NCOA2/3_DUF4927.
DR   InterPro; IPR028822; NCOA2_bHLH.
DR   InterPro; IPR009110; Nuc_rcpt_coact.
DR   InterPro; IPR014920; Nuc_rcpt_coact_Ncoa-typ.
DR   InterPro; IPR037077; Nuc_rcpt_coact_Ncoa_int_sf.
DR   InterPro; IPR017426; Nuclear_rcpt_coactivator.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   InterPro; IPR014935; SRC/p160_LXXLL.
DR   PANTHER; PTHR10684; NUCLEAR RECEPTOR COACTIVATOR; 1.
DR   PANTHER; PTHR10684:SF2; NUCLEAR RECEPTOR COACTIVATOR 2; 1.
DR   Pfam; PF07469; DUF1518; 1.
DR   Pfam; PF16279; DUF4927; 1.
DR   Pfam; PF16665; NCOA_u2; 1.
DR   Pfam; PF08815; Nuc_rec_co-act; 1.
DR   Pfam; PF00989; PAS; 1.
DR   Pfam; PF14598; PAS_11; 1.
DR   Pfam; PF08832; SRC-1; 1.
DR   PIRSF; PIRSF038181; Nuclear_receptor_coactivator; 1.
DR   SMART; SM01151; DUF1518; 1.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00091; PAS; 1.
DR   SUPFAM; SSF47459; HLH, helix-loop-helix DNA-binding domain; 1.
DR   SUPFAM; SSF69125; Nuclear receptor coactivator interlocking domain; 1.
DR   SUPFAM; SSF55785; PYP-like sensor domain (PAS domain); 2.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Biological rhythms; Isopeptide bond;
KW   Methylation; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   CHAIN           2..1465
FT                   /note="Nuclear receptor coactivator 2"
FT                   /id="PRO_0000094404"
FT   DOMAIN          26..83
FT                   /note="bHLH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT   DOMAIN          119..183
FT                   /note="PAS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00140"
FT   REGION          1..40
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          449..528
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          547..741
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          691..743
FT                   /note="CASP8AP2-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q61026"
FT   REGION          730..1121
FT                   /note="Interaction with BMAL1"
FT                   /evidence="ECO:0000250|UniProtKB:Q61026"
FT   REGION          1052..1075
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1311..1330
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           641..645
FT                   /note="LXXLL motif 1"
FT   MOTIF           690..694
FT                   /note="LXXLL motif 2"
FT   MOTIF           745..749
FT                   /note="LXXLL motif 3"
FT   MOTIF           878..882
FT                   /note="LXXLL motif 4"
FT   MOTIF           1079..1087
FT                   /note="LLXXLXXXL motif"
FT   COMPBIAS        11..40
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        449..488
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        505..528
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        556..572
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        637..678
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        712..729
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         29
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         338
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61026"
FT   MOD_RES         396
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         487
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         493
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         499
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         554
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         565
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         636
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61026"
FT   MOD_RES         640
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         682
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         699
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         736
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         771
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         780
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         785
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         864
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61026"
FT   MOD_RES         874
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61026"
FT   MOD_RES         1173
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         1177
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         1190
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         1196
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         1203
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         1221
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         1240
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61026"
FT   MOD_RES         1261
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   MOD_RES         1266
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   CROSSLNK        239
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   CROSSLNK        648
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   CROSSLNK        705
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   CROSSLNK        731
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   CROSSLNK        785
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   CROSSLNK        1455
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:Q15596"
FT   HELIX           689..695
FT                   /evidence="ECO:0007829|PDB:3L03"
FT   HELIX           744..748
FT                   /evidence="ECO:0007829|PDB:1XLS"
SQ   SEQUENCE   1465 AA;  159436 MW;  36625B573EB0B39C CRC64;
     MSGMGENTSD PSRAETRKRK ECPDQLGPSP KRSTEKRNRE QENKYIEELA ELIFANFNDI
     DNFNFKPDKC AILKETVKQI RQIKEQEKAA AANIDEVQKS DVSSTGQGVI DKDALGPMML
     EALDGFFFVV NLEGNVVFVS ENVTQYLRYN QEELMNKSVY SILHVGDHTE FVKNLLPKSM
     VNGGSWTGEP PRRNSHTFNC RMLVKPLPDS EEEGHDNQEA HQKYETMQCF AVSQPKSIKE
     EGEDKQSCLI CVARRVPMKE RPALPSSESF TTRQDLQGKI TFLDTSTMRD AMKPGWEDLV
     RRCIQKFHTQ HEGESLSYAK RHHHEVLRQG LAFSQIYRFS LSDGTLVAAQ TKSKLIRSQT
     TNEPQLVISI HMLHREQNVC VMNPDLTGQA MGKPLSPMSS SSPARQAMCS GNPGQDVALG
     SNMNFPMNGP REQMSMPMGR FGGSGGMNHV SGMQATTPQG SNYALKMNSP SQSSPGLNPG
     QPSSVLSPRH RMSPGVAGSP RVPPSQFSPA GSLHSPAGVC SSTGNSHSYT NSSLNALQAL
     SEGHGVSLGP SLASPDLKMG NSQNSPVNMN PPPLSKMGSL DSKDCFGLYG EPSEGTTGQA
     QASCHPEEQK RPNDSSMPQA ASEDRAEGHS RLHESKGQTK LLQLLTTKSD QMEPSPLPSS
     LSDTNKDSTG SLPGPGSTHG TSLKEKHKIL HRLLQDSSSP VDLAKLTAEA TGKELNQESS
     GTAPGSEVTV KQEPASPKKK ENALLRYLLD KDDTKDIGLP EITPKLERLD SKTDPASNTK
     LIAMKTVKEE VSFEPSDQPG SELDNLEEIL DDLQNSQLPQ LFPDTRPGAP TGSVDKQAII
     NDLMQLTADS SPVTPVGAQK AALRMSQSTF NNPRPGQLGR LLPNQNLPLD ITLQSPTGAG
     PFPPIRNSSP YSVIPQPGMM GNQGMLGSQG NLGNNSTGMI GSSTSRSSMP SGEWAPQSPA
     VRVTCAATTG AMNRPIQGGM IRNPTASIPM RANSQPGQRQ MLQPQVMNIG PSELEMNMGG
     PQYNQQQAPP NQTAPWPESI LPIDQASFGS QNRHPFGSSP DDLLCPHPAA ESPSDEGALL
     DQLYLALRNF DGLEEIDRAL GIPELVSQSQ AVDPEQFSSQ ESSMMLEQKP PVFPQQYASQ
     TQMAQGSYNP MQDPNFHTMG QRPNYTTLRM QPRPGLRPTG IVQNQPNQLR LQLQHRLQAQ
     QNRQPLMNQI SGVSNVNLTL RPGVPTQAPI NAQMLAQRQR EILNQHLRQR QMHQQQQVQQ
     RTLMMRGQGL NMTPSMVAPT GLPAAMSNPR IPQANAQQFP FPPNYGISQQ PDPGFTGATT
     PQSPLMSPRM AHTQSPMMQQ SQANPAYQPA SDINGWAQGS MGGNSMFSQQ SPPHFGQQAN
     TSMYNNNMNI NVSMATNTAG LSNMNQMTGQ MSMTSVTSVP TSGLSSMGPE QVNDPALRGS
     SLFTTNQLPG MDMIKQEGDG SRKYC
//
